ASX:RCE Recce Pharmaceuticals (RCE) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free RCE Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume630,087 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Recce Pharmaceuticals alerts: Email Address Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Recce Pharmaceuticals Stock (ASX:RCE)Recce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous which provides serious/life-threatening bacterial infections, including sepsis which is in the phase 1 trial; urinary tract infections, including urosepsis; rapid infusions sepsis in the phase 2 trial; and R327 Topical offers wound infections, including infected burns; and diabetic foot ulcer infections in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Mycobacterium abscessus which is in phase 1 clinical trial; bacterial sinusitis; and additional TBA. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.Read More Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> RCE Stock News HeadlinesApril 17, 2024 | finance.yahoo.comRecce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)April 10, 2024 | finance.yahoo.comRecce Pharmaceuticals Provides Business UpdateApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...April 9, 2024 | finance.yahoo.comRecce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024April 4, 2024 | seekingalpha.comRecce pharmaceuticals granted new patent in Israel for anti-infectivesApril 4, 2024 | finance.yahoo.comRecce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-InfectivesMarch 22, 2024 | finance.yahoo.comRecce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP PortfolioMarch 19, 2024 | msn.comRecce hits milestone in Phase I/II trial for UTIs and urosepsisApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 19, 2024 | finance.yahoo.comRecce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and UrosepsisMarch 18, 2024 | proactiveinvestors.com.auRecce Pharmaceuticals hits major milestone in R327 clinical trial for UTI/urosepsisMarch 18, 2024 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Recce Pharmaceuticals StockMarch 14, 2024 | finance.yahoo.comRecce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and UrosepsisMarch 13, 2024 | finance.yahoo.comRecce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual MeetingMarch 12, 2024 | finance.yahoo.comRecce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) AdvanceFebruary 29, 2024 | finance.yahoo.comRecce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research InstituteFebruary 27, 2024 | finance.yahoo.comRecce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot InfectionsFebruary 9, 2024 | au.finance.yahoo.comRecce Pharmaceuticals Ltd (RCE.AX)February 7, 2024 | finance.yahoo.comRecce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical ProgramFebruary 6, 2024 | afr.comRecce Pharmaceuticals LtdJanuary 14, 2024 | finance.yahoo.comThose who invested in Recce Pharmaceuticals (ASX:RCE) five years ago are up 247%December 19, 2023 | finance.yahoo.comRecce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development ProgramDecember 18, 2023 | finance.yahoo.comRecce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against GonorrheaDecember 17, 2023 | au.investing.comRecce Pharmaceuticals awarded A$11 million Advanced Overseas Finding for anti-viral R&D costsDecember 14, 2023 | au.investing.comRecce Pharmaceuticals awarded $43.7 million Advanced Overseas Finding for synthetic anti-infective development programDecember 13, 2023 | au.investing.comRecce Pharmaceuticals achieves strong anti-bacterial effect against deadly Neisseria gonorrhoeae pathogen in animal modelNovember 27, 2023 | finance.yahoo.comRecce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-InfectivesSee More Headlines Receive RCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recce Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2019Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:RCE CUSIPN/A CIKN/A Webwww.recce.com.au Phone61 2 8075 4585FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,320,000.00 Net Margins-167.74% Pretax MarginN/A Return on Equity-1,277.62% Return on Assets-167.19% Debt Debt-to-Equity Ratio455.33 Current Ratio1.04 Quick Ratio4.81 Sales & Book Value Annual Sales$6.75 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow13.57 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares203,700,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.29 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. John K. A. Prendergast Ph.D. (Age 70)Executive Chairman of the Board Comp: $369.85kMr. James Hamilton-Bray Graham GAICDCEO, MD & Executive DirectorMs. Michele Keryn Diliza BA (Journ)BSc (Med Sci), Chief Scientific Director & Executive DirectorDr. Justin WardPrincipal Quality Chemist & Executive DirectorMr. Arthur KollarasPrincipal Engineer & Head of ManufacturingDr. Alan W. Dunton B.Sc. (Age 70)M.D., Chief Medical Advisor & Independent Non Executive Director Comp: $72.5kMr. Justin ReynoldsChief Financial OfficerMr. Daniel Astudillo B.A.B.Com., M.B.A., Head of MarketingMs. Maggie NiewidokCompany SecretaryMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersMichele DiliziaSold 836,405 sharesTotal: $334,562.00 ($0.40/share)James GrahamSold 262,347 sharesTotal: $127,238.30 ($0.49/share)James GrahamBought 500,000 shares on 6/22/2023Total: $295,000.00 ($0.59/share) RCE Stock Analysis - Frequently Asked Questions How were Recce Pharmaceuticals' earnings last quarter? Recce Pharmaceuticals Ltd (ASX:RCE) released its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.01) EPS for the quarter. Recce Pharmaceuticals had a negative trailing twelve-month return on equity of 1,277.62% and a negative net margin of 167.74%. What other stocks do shareholders of Recce Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Recce Pharmaceuticals investors own include ASE Technology (ASX), FlexiGroup Limited (FXL.AX) (FXL), Immutep (IMMP), Mavenir (MVNR), Applied Optoelectronics (AAOI), 5G Networks (5GN), Ilika (IKA), Insignia Financial (IFL), Turtle Beach (HEAR) and First Graphene (FGR). This page (ASX:RCE) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressPentagon contract could send this $2 AI stock soaringBehind the MarketsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recce Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
